Clinical and palliative care outcomes for patients of poor performance status treated with antiprogrammed death-1 monoclonal antibodies for advanced melanoma.

MLA

Wong, Annie, et al. “Clinical and Palliative Care Outcomes for Patients of Poor Performance Status Treated with Antiprogrammed Death-1 Monoclonal Antibodies for Advanced Melanoma.” Asia Pacific Journal of Clinical Oncology, vol. 13, no. 6, Dec. 2017, pp. 385–90. EBSCOhost, https://doi.org/10.1111/ajco.12702.

APA

Wong, A., Williams, M., Milne, D., Morris, K., Lau, P., Spruyt, O., Fullerton, S., & McArthur, G. (2017). Clinical and palliative care outcomes for patients of poor performance status treated with antiprogrammed death-1 monoclonal antibodies for advanced melanoma. Asia Pacific Journal of Clinical Oncology, 13(6), 385–390. https://doi.org/10.1111/ajco.12702

Chicago

Wong, Annie, Molly Williams, Donna Milne, Kortnye Morris, Peter Lau, Odette Spruyt, Sonia Fullerton, and Grant McArthur. 2017. “Clinical and Palliative Care Outcomes for Patients of Poor Performance Status Treated with Antiprogrammed Death-1 Monoclonal Antibodies for Advanced Melanoma.” Asia Pacific Journal of Clinical Oncology 13 (6): 385–90. doi:10.1111/ajco.12702.